Life Scientist > Biotechnology

PsiMedica enters revenue sharing agreement

19 June, 2003 by Melissa Trudinger

Perth nanotechnology company PsiVida announced that its British subsidiary PsiMedica has entered into a revenue sharing agreement with Texas Christian University (TCU) over an invention with applications in orthopaedics and tissue engineering.


Bio Pharma signs $3.5m contract

18 June, 2003 by Pete Young

A $3.5 million dollar conditional contract with an Asian company could give startup Bio Pharma Pty Ltd the push it needs to move into commercial production.


Peptech reports 'outstanding' results

18 June, 2003 by Jeremy Torr

Biotech Peptech announced what it described as "outstanding" results from pre-clinical trials on its anti-Tumour Necrosis Factor (anti-TNF) antibody as a treatment for rheumatoid arthritis (RA).


Imugene completes $2m placement

17 June, 2003 by Melissa Trudinger

Veterinary biotechnology company Imugene has completed a $AUD2 million placement to institutional and professional high net worth investors.


Genetic Technologies receives $US150,000 for patent license

16 June, 2003 by Melissa Trudinger

Texan company Inguran has paid $US150,000 to Melbourne-based Genetic Technologies to use the company's non-coding patents for genetic testing of livestock in the USA, Colombia and Brazil.


Laser lab to improve artificial heart design

13 June, 2003 by Jeremy Torr

A $1.5million laser diagnostic laboratory could help researchers cut down thrombosis risks for artificial heart patients, using the latest Particle Image Velocimetry (PIV).


Tissue Growth and Repair CRC backs a winner

13 June, 2003 by Jeremy Torr

Shooting the nag for not winning could be a thing of the past thanks to the CRC for Tissue Growth and Repair’s work on IGF-I (insulin-like growth factor-I) to stimulate tissue repair.


Imugene itching to launch product

12 June, 2003 by Jeremy Torr

Vet biotech Imugene is pinning big hopes on its recombinant gene-based flea control vaccine currently on trial at Murdoch University.


Genetraks invests $1m to fast-track development

11 June, 2003 by Pete Young

Cashed-up young biotech Genetraks Pty Ltd is investing more than $1 million to dramatically accelerate the time to market of its gene-based diagnostic and monitoring tools.


MIF blocking drugs being developed by Cortical

11 June, 2003 by Melissa Trudinger

One of Australia's newest start-up companies has spun out of Monash University with a focus on finding therapeutics targeting the macrophage inhibitory factor (MIF).


GM's lambs are inviting slaughter

11 June, 2003 by Graeme O'Neill

Graeme O'Neill discovers that the biotech community needs a whole new strategy to win points on GM crops


Africa needs GM crops: scientist

10 June, 2003 by Graeme O'Neill

African plant geneticist Dr Florence Wambugu has accused Western activists, seeking to block the introduction of genetically modified (GM) crops in Africa, of having “no understanding” of the needs of African farmers and communities.


GroPep, CSL amend agreement

10 June, 2003 by Melissa Trudinger

Adelaide company GroPep and cell culture reagent distribution partner CSL have amended their sales and distribution agreement to reflect expected demand for GroPep's growth factor products by extending the agreed minimum sales targets from the 2005-2006 financial year through to the end of the 2010 financial year, when the agreement ends.


Trial tapeworm vaccine takes the bacon

06 June, 2003 by Jeremy Torr

Initial research by a PhD student at the Bioproducts Cooperative Research Centre (CRC) in Melbourne has shown an edible tapeworm vaccine is possible -- for pigs.


Benitec locks in US and UK patents for RNAi tech

05 June, 2003 by Pete Young

Gene silencing company Benitec has locked in place US and UK patents for the technology which underpins a recent global licensing pact signed by the Brisbane biotech.


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd